Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer

被引：15

作者：

Ban, Marija ^{[1
]}

Mise, Branka Petric ^{[1
]}

Majic, Ana ^{[1
]}

Drazic, Ivanka ^{[1
]}

Vrdoljak, Eduard ^{[1
]}

机构：

[1] Univ Hosp Ctr Split, Split Sch Med, Dept Oncol & Radiotherapy, Spinciceva 1, Split 21000, Croatia

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 06期

关键词：

breast; cancer; heavily pretreated; HER2-; hormone receptor positive; metastatic; palbociclib; EVEROLIMUS PLUS EXEMESTANE; 4/6 INHIBITOR PALBOCICLIB; ENDOCRINE RESISTANCE; GROWTH-FACTOR; PHASE-II; ABEMACICLIB; COMBINATION; EXPRESSION; LETROZOLE;

D O I：

10.2217/fon-2017-0491

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2-metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. Methods: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. Results: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months; median overall survival was 11 months. Treatment was well tolerated. Conclusion: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.

引用

页码：537 / 544

页数：8

共 24 条

[1] Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus [J].

Altucci, L ;

Addeo, R ;

Cicatiello, L ;

Germano, D ;

Pacilio, C ;

Battista, T ;

Cancemi, M ;

Petrizzi, VB ;

Bresciani, F ;

Weisz, A .

ENDOCRINOLOGY, 1997, 138 (03) :978-984

[2] Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer [J].

Bae, Soo Youn ;

Kim, Sangmin ;

Lee, Jun Ho ;

Lee, Hyun-chul ;

Lee, Se Kyung ;

Kil, Won Ho ;

Kim, Seok Won ;

Lee, Jeong Eon ;

Nam, Seok Jin .

BMC CANCER, 2015, 15

[3] What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study [J].

Bakker, J. L. ;

Wever, K. ;

van Waesberghe, J. H. ;

Beeker, A. ;

Meijers-Heijboer, H. ;

Konings, I. R. ;

Verheul, H. M. W. .

CANCER EPIDEMIOLOGY, 2015, 39 (06) :848-853

[4] Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E [J].

Butt, AJ ;

McNeil, CM ;

Musgrove, EA ;

Sutherland, RL .

[5] ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J].

Cardoso, F. ;

Costa, A. ;

Norton, L. ;

Senkus, E. ;

Aapro, M. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Blackwell, K. L. ;

Cardoso, M. J. ;

Cufer, T. ;

El Saghir, N. ;

Fallowfield, L. ;

Fenech, D. ;

Francis, P. ;

Gelmon, K. ;

Giordano, S. H. ;

Gligorov, J. ;

Goldhirsch, A. ;

Harbeck, N. ;

Houssami, N. ;

Hudis, C. ;

Kaufman, B. ;

Krop, I. ;

Kyriakides, S. ;

Lin, U. N. ;

Mayer, M. ;

Merjaver, S. D. ;

Nordstrom, E. B. ;

Pagani, O. ;

Partridge, A. ;

Penault-Llorca, F. ;

Piccart, M. J. ;

Rugo, H. ;

Sledge, G. ;

Thomssen, C. ;

van't Veer, L. ;

Vorobiof, D. ;

Vrieling, C. ;

West, N. ;

Xu, B. ;

Winer, E. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :1871-1888

[6] CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment [J].

DeMichele, Angela ;

Clark, Amy S. ;

Tan, Kay See ;

Heitjan, Daniel F. ;

Gramlich, Kristi ;

Gallagher, Maryann ;

Lal, Priti ;

Feldman, Michael ;

Zhang, Paul ;

Colameco, Christopher ;

Lewis, David ;

Langer, Melissa ;

Goodman, Noah ;

Domchek, Susan ;

Gogineni, Keerthi ;

Rosen, Mark ;

Fox, Kevin ;

O'Dwyer, Peter .

CLINICAL CANCER RESEARCH, 2015, 21 (05) :995-1001

[7]

Di Leo A, 2017, ANN ONCOL, V28, pv605

[8] MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer [J].

Dickler, Maura N. ;

Tolaney, Sara M. ;

Rugo, Hope S. ;

Cortes, Javier ;

Dieras, Veronique ;

Patt, Debra ;

Wildiers, Hans ;

Hudis, Clifford A. ;

O'Shaughnessy, Joyce ;

Zamora, Esther ;

Yardley, Denise A. ;

Frenzel, Martin ;

Koustenis, Andrew ;

Baselga, Jose .

CLINICAL CANCER RESEARCH, 2017, 23 (17) :5218-5224

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012 [J].

Ferlay, J. ;

Steliarova-Foucher, E. ;

Lortet-Tieulent, J. ;

Rosso, S. ;

Coebergh, J. W. W. ;

Comber, H. ;

Forman, D. ;

Bray, F. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) :1374-1403

← 1 2 3 →